Procter & Gamble v. Johnson & Johnson

Lawsuit charging J&J with unfair competition in the hiring of two former P&G executives -- Neal Matheson and Steven Shaya -- is settled. J&J's counterclaim regarding P&G's hiring of former J&J executive Bruce Semple also has been resolved. P&G commented that "Matheson and Shaya will be restricted from working in critical areas of J&J's skin care business for three years." J&J said that Semple would be restricted by "similar" terms. J&J said P&G never filed an amended complaint that would have raised questions about Matheson and Shaya's possible involvement in J&J's acquisition of Neutrogena ("The Tan Sheet" Sept. 12, p. 11)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By 

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By 

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.